

# ARE SINGLE AGENT TKIs STILL STANDARD OF CARE IN EGFR MUTANT NON-SMALL CELL LUNG CANCER OR SHOULD THEY BE COMBINED WITH OTHER AGENTS?

## Chair

Myung-Ju Ahn, Republic of Korea

## Co-Chair

Martin Reck, Germany

**WEDNESDAY 23 SEPTEMBER 2020**

13:00-14:30 CHANNEL 1

13:00	Is Osimertinib the best single agent in 1 <sup>st</sup> line?	Myung-Ju Ahn Seoul, Republic of Korea
13:15	Should chemotherapy be combined upfront with EGFR TKI?	Ross Soo Singapore
13:30	Is a combination of anti-angiogenic with EGFR TKI a new standard?	Martin Reck Grosshansdorf, Germany
13:45	Do immune checkpoint inhibitors work in combination with EGFR TKIs?	Edward Garon Santa Monica, CA, USA
14:00	What is the best sequencing across multiple lines of therapy?	Enriqueta Felip Barcelona, Spain
14:10	Conclusions	Myung-Ju Ahn Seoul, Republic of Korea
14:15	Live Q&A	

This educational activity is provided by ESMO and supported by Lilly.

